What's Going On With Candel Therapeutics Stock On Friday?
Portfolio Pulse from Vandana Singh
Candel Therapeutics Inc (NASDAQ:CADL) shares surged on heavy trading volume following positive interim data from a phase 2 clinical trial of CAN-2409 for non-metastatic pancreatic cancer, showing prolonged survival rates. Additionally, updated data from a phase 1b trial of CAN-3110 for recurrent high-grade glioma showed nearly double the expected median overall survival. Shares are up 15.20% in premarket trading.
April 05, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Candel Therapeutics Inc shares rose significantly due to positive results from clinical trials of CAN-2409 and CAN-3110, indicating potential for substantial impact on patient survival in pancreatic cancer and recurrent high-grade glioma.
The significant increase in Candel Therapeutics' stock price is directly attributed to the announcement of positive interim data from its clinical trials, which suggests a strong potential for its treatments in the market. The heavy trading volume further indicates high investor interest and optimism about the company's future prospects.
CONFIDENCE 90
IMPORTANCE 95
RELEVANCE 100